跳至主要内容
临床试验/NCT04893057
NCT04893057已完成不适用

SARS-CoV-2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang

Centre Hospitalier Universitaire de Besancon1 个研究点 分布在 1 个国家目标入组 797 人开始时间: 2022年9月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
797
试验地点
1
主要终点
Anti-SARS-CoV-2 spike protein total IgG

研究概览

简要总结

The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pregnant women
  • Adult female
  • Admitted to hospital for live birth
  • Informed consent
  • Affiliated to the French social security health insurance scheme
  • Blood donors
  • Adult male or female
  • Qualified for whole blood donation (up to 70 years old in France)
  • Informed consent
  • Affiliated to the French social security health insurance scheme

排除标准

  • Legal incapacity or limited legal capacity
  • Subject without health insurance coverage
  • Exclusion period of another study or exclusion period of the French national healthy volunteer registry

结局指标

主要结局

Anti-SARS-CoV-2 spike protein total IgG

时间窗: at inclusion

Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay

次要结局

  • Anti-SARS-CoV-2 nucleocapsid protein total IgG(at inclusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验